Darzalex Daratumumab Injection, Janssen

Introduction to Darzalex 400mg Injection

Darzalex 400mg injection is a targeted therapy for cancer containing the active ingredient Daratumumab, which belongs to the group of medicine called monoclonal antibodies. Monoclonal antibodies are proteins that recognize and attach to the specific target, killing the cancer cells. It is used to treat a type of cancer called multiple myeloma (bone marrow cancer) in adults 18 years or older. Report to your doctor if you have ever had a hepatitis B infection; this medicine may cause the hepatitis B virus to become active again. This medicine can decrease platelets (helps in blood clotting) and white blood cell counts (helps fight infections). 

Do not take a Darzalex 400mg injection if you are allergic to Daratumumab or other medicine ingredients. This medicine is not recommended for children and adolescents. Inform your doctor if you get any infusion-related reactions, such as swollen face, lips, mouth, tongue, or throat. If you notice any infusion reactions, you need other medicine, or the infusion will be slowed down or stopped. 

Consult your doctor if you are on a salt-controlled diet, as this medicine contains sodium. Tell your physician if you have a history of breathing problems (asthma or chronic obstructive pulmonary disease) or had shingles before taking Darzalex 400mg. This medicine can change the results of blood tests to match your blood type. You must tell your healthcare provider you are being treated with this medicine before receiving blood transfusions. Inform your doctor if you are pregnant or planning to get pregnant. Use effective contraception during and after the treatment for three months.